Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Reconciliation of earnings (loss) attributable to common stockholders for basic and diluted earnings (loss) per share

The following is a reconciliation of the Company’s income (loss) attributable to common stockholders for basic and diluted income (loss) per share (in thousands):

	Three Months Ended March 31,
	2022		2023
Net income (loss) attributable to Antero Resources Corporation—common shareholders	$	(156,419)		213,431
Add: Interest expense for 2026 Convertible Notes		—		616
Less: Tax-effect of interest expense for 2026 Convertible Notes		—		(132)
Net income (loss) attributable to Antero Resources Corporation—common shareholders and assumed conversions	$	(156,419)		213,915
Income (loss) per share—basic	$	(0.50)		0.72
Income (loss) per share—diluted	$	(0.50)		0.69
Weighted average common shares outstanding—basic		314,081		296,763
Weighted average common shares outstanding—diluted		314,081		311,846

Reconciliation of basic weighted average shares outstanding to diluted weighted average shares outstanding

The following is a reconciliation of the Company’s basic weighted average shares outstanding to diluted weighted average shares outstanding during the periods presented (in thousands):

	Three Months Ended March 31,
	2022	2023
Basic weighted average number of shares outstanding	314,081	296,763
Add: Dilutive effect of RSUs	—	2,150
Add: Dilutive effect of PSUs	—	1,060
Add: Dilutive effect of 2026 Convertible Notes	—	11,873
Diluted weighted average number of shares outstanding	314,081	311,846
Weighted average number of outstanding securities excluded from calculation of diluted income (loss) per common share (1):
RSUs	4,878	969
PSUs	3,443	414
Stock options	351	324
2026 Convertible Notes	18,778	—

(1) The potential dilutive effects of these awards were excluded from the computation of income (loss) per common share—diluted because the inclusion of these awards would have been anti-dilutive.